|Abstract:||3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof are disclosed. The compound is of use in the preparation of pharmaceutical compositions, particularly for intranasal formulations, for use in the treatment of conditions associated with cephalic pain, in particular migraine.|
|Inventor(s):||Craig; Joanne (Ware, GB3), Crookes; Derek L. (Ware, GB3), Skittrall; Stephen J. (Ware, GB3)|
|Assignee:||Glaxo Group Limited (London, GB2)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Compound; Dosage form; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9026998||Dec 12, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||230||► subscribe|
|African Regional IP Organization (ARIPO)||9100339||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.